Alvotech
ALVO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001898416
No open-market purchases or sales by Alvotech insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $157.4M in total; Oaktree Capital is the only superinvestor holding it.
Other share classesALVOW
13F holders, Q3 2023
Institutional positions in Alvotech as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +2 vs. Q2 2023
- Shares held
- 17.8M
- +216.3K (+1.2%) vs. Q2 2023
- Total value
- $159.7M
- +$26.2M (+19.6%) vs. Q2 2023
- New holders
- 4
- 4 more added
- Sold out
- 2
- 7 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 72 | $157.4M |
| Q1 2026 | 57 | $57.3M |
| Q4 2025 | 49 | $78.1M |
| Q3 2025 | 66 | $127.9M |
| Q2 2025 | 53 | $156.0M |
| Q1 2025 | 51 | $159.2M |
| Q4 2024 | 45 | $199.6M |
| Q3 2024 | 32 | $178.2M |
| Q2 2024 | 31 | $174.0M |
| Q1 2024 | 22 | $172.4M |
| Q4 2023 | 18 | $196.8M |
| Q3 2023 | 19 | $159.7M |
| Q2 2023 | 17 | $133.5M |
| Q1 2023 | 17 | $244.6M |
| Q4 2022 | 11 | $184.7M |
| Q3 2022 | 14 | $140.6M |
| Q2 2022 | 17 | $157.8M |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Alvotech; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Oaktree Capital Management LPSuperinvestorOaktree Capital | 5,043,505 | $46.0M | 0.70% | −1,715,655−25.4% | Reduced |
| Bracebridge Capital, LLC | 4,360,524 | $39.8M | 35.60% | 00.0% | Unchanged |
| Vanguard Group Inc | 2,881,396 | $26.3M | 0.00% | +2,881,396 | New |
| Littlejohn & Co LLC | 1,132,391 | $10.3M | 8.99% | 00.0% | Unchanged |
| Sculptor Capital LP | 1,086,347 | $9.95M | 0.24% | 00.0% | Unchanged |
| Temasek Holdings (Private) Ltd | 1,000,000 | $9.12M | 0.05% | 00.0% | Unchanged |
| Suvretta Capital Management, LLC | 928,402 | $8.47M | 0.46% | −71,598−7.2% | Reduced |
| Oaktree Fund Advisors, LLC | 471,253 | $4.30M | 4.31% | −352,944−42.8% | Reduced |
| Lodbrok Capital LLP | 688,678 | $3.85M | 2.00% | −64,852−8.6% | Reduced |
| Geode Capital Management, LLC | 57,001 | $519.8K | 0.00% | +18,152+46.7% | Added |
| National Asset Management, Inc. | 50,000 | $456.0K | 0.01% | +25,000+100.0% | Added |
| Mariner, LLC | 33,706 | $307.4K | 0.00% | +7,545+28.8% | Added |
| Wolverine Asset Management LLC | 17,857 | $162.9K | 0.00% | +88+0.5% | Added |
| Bank of America Corp | 10,000 | $91.2K | 0.00% | −5,000−33.3% | Reduced |
| JPMorgan Chase & Co | 8,446 | $77.0K | 0.00% | −51,783−86.0% | Reduced |
| Royal Bank of Canada | 190 | $2.00K | 0.00% | −191−50.1% | Reduced |
| UBS Group AG | 78 | $711 | 0.00% | +78 | New |
| Qube Research & Technologies Ltd | 16 | $146 | 0.00% | +16 | New |
| Morgan Stanley | 1 | $9 | 0.00% | +1 | New |
| Farallon Capital Management, L.L.C. | 0 | $0 | 0.00% | −437,110−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −16,855−100.0% | Sold out |